Table 1.
Base case analysis–methods–unit cost for healthcare resources, utility, and disutility values (95% CI)a,b (costs in €2020).
| Model main items | Point estimate (95% CI) | Source | |
|---|---|---|---|
| OAG/OHT stages 0-5 | |||
| Drugs | |||
| OAG/OHT medications c,d | |||
| STN1013001 | €0.30 | Santen GmbH2020 | |
| Latanoprost | €0.24 | IQVIA [31], Ministère des Affaires Sociales et de la Santé [32] | |
| Add-on therapies d,e | |||
| Acetazolamide | €0.16 | IQVIA [31], Ministère des Affaires Sociales et de la Santé [32] | |
| Brimonidine | €0.12 | IQVIA [31], Ministère des Affaires Sociales et de la Santé [32] | |
| Brinzolamide | €0.12 | IQVIA [31], Ministère des Affaires Sociales et de la Santé [32] | |
| Brinzolamide + brimonidine | €0.28 | IQVIA [31], Ministère des Affaires Sociales et de la Santé [32] | |
| Dorzolamide | €0.14 | IQVIA [31], Ministère des Affaires Sociales et de la Santé [32] | |
| Timolol | €0.18 | IQVIA [31], Ministère des Affaires Sociales et de la Santé [32] | |
| Timolol + dorzolamide | €0.20 | IQVIA [31], Ministère des Affaires Sociales et de la Santé [32] | |
| OSD therapies e | |||
| Cyclosporin | €3.67 | IQVIA [31], Ministère des Affaires Sociales et de la Santé [32] | |
| Preservative-free lubricant | €0.27 | IQVIA [31], Ministère des Affaires Sociales et de la Santé [32] | |
| Healthcare procedures f | |||
| Breakup time test | €19.20 | Sécurité Sociale [33] (elaborated on: Tarif Secteur 1; code: 02.01.06.03 BBQP001) | |
| (€15.44; €22.96) | |||
| Diurnal curve of intraocular pressure measurement | €41.66 (€33.49; €49.83) | Sécurité Sociale [33] (elaborated on: Tarif Secteur 1; code: 02.01.06.01 BHQP001) | |
| Fluorescein test | €19.20 | Sécurité Sociale [33] (elaborated on: Tarif Secteur 1; code: 02.01.06.03 BBQP001) | |
| (€15.44; €22.96) | |||
| Gonioscopy | €17.28 (€13.89; €20.67) | Sécurité Sociale [33] (Tarif Secteur 1; code: 02.01.06.01 BHQP002) | |
| Lissamine test | €19.20 | Sécurité Sociale [33] (elaborated on: Tarif Secteur 1; code: 02.01.06.03 BBQP001) | |
| (€15.44; €22.96) | |||
| Optical coherence tomography retinal nerve fiber layer | €56.54 (€45.46; €67.62) | Sécurité Sociale [33] (Tarif Secteur 1; code: 02.01.05 BZQK001) | |
| Retinal nerve fiber thickness assessment | €26.78 (€21.53; €32.03) | Sécurité Sociale [33] (Tarif Secteur 1; code: 02.01.04 BGQP009) | |
| Schirmer test | €19.20 | Sécurité Sociale [33] (Tarif Secteur 1; code: 02.01.06.03 BBQP001) | |
| (€15.44; €22.96) | |||
| Slit lamp examination | €28.29 (€24.92; €37.06) | Sécurité Sociale [33] (Tarif Secteur 1; code: 02.01.06.03 BGQP002) | |
| Tonometry | €41.66 (€11.21; € 16.67) | Sécurité Sociale [33] (Tarif Secteur 1; code: 02.01.06.01 BHQP001) | |
| Visual field test | €39.43 | Sécurité Sociale [33] (Tarif Secteur 1; code: 02.01.06.02 BLQP004) | |
| (€31.70; € 47.16) | |||
| Specialist visits | |||
| Ophthalmologist | €25.32 (€20.36; €30.28) | Sécurité Sociale [33] (Tarif Secteur 1; code: 02.01.06.02 BLQP010) | |
| Utility and disutility values g | STN1013001 h | Latanoprost 1 | |
| OAG/OHT stage 0 | 0.900 (0.885; 0.915) | 0.900 (0.884; 0.915) | van Gestel et al. [29] |
| OAG/OHT stage 1 | 0.897 (0.880; 0.913) | 0.890 | Experts' opinion |
| (0.872; 0.908) | |||
| OAG/OHT stage 2 | 0.879 (0.860; 0.896) | 0.866 (0.845; 0.885) | Experts' opinion |
| OAG/OHT stage 3 | 0.862 (0.840; 0.883) | 0.849 (0.825; 0.871) | Experts' opinion |
| OAG/OHT stage 4 | 0.825 (0.795; 0.853) | 0.808 (0.776; 0.838) | Experts' opinion |
| OAG/OHT stage 5 | 0.790 (0.750; 0.828) | 0.790 (0.748; 0.829) | van Gestel et al. [29], |
| OSD-related disutility | −0.120 | −0.120 | Canadian Agency for drugs and Technology in Health [30] |
| (−0.231; −0.045) | (−0.231; −0.045) | ||
| Death | 0.000 (−) | 0.000 (−) | Drummond et al. [15], Neumann et al. [16] |
a95% CI was calculated assuming a normal probability distribution [14,34].b95% CI was not calculated for the unit cost of drugs since they are exogenous variables [34].c Medications refer to STN1013001 and Latanoprost only. dCost per diem calculated on ex-factory price. eAdd-on therapies prescribed in addition to STN1013001 or Latanoprost due to poor IOP control. fBeing not funded by French health system, LipiView test was not included in cost calculation. g95% CI for utility and disutility values was calculated assuming a beta and a gamma probability distribution, respectively [14]. hNumber of observations per OAG/OHT stage (female %): 0 = 1560 (50.00%%); 1 = 1280 (50.00%); 2 = 1280 (50.00%); 3 = 1000 (50.00%); 4 = 650 (50.00%); and 5 = 415 (50.00%). iNumber of observations per OAG/OHT stage: 0 = 1460 (50.00%); 1 = 1160 (57.43%); 2 = 1150 (50.00%); 3 = 930 (50.00%); 4 = 61 (50.00%); and 5 = 390 (50.00%). CI = confidence interval; IOP = intraocular pressure; OAG/OHT = open-angle glaucoma/ocular hypertension; and OSD = ocular surface disease. Bold fonts were used to define different sets of items that were used to populate the Markov model.